A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
Eligible age
18–80 yrs
Accepts
All genders
Locations
20 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This is a Phase 2, multicenter, platform study in adult participants with IBD (moderately to severely active Crohn's Disease or Ulcerative Colitis). The primary goal of this study is to assess the safety and efficacy of multiple investigational drugs.
Sponsor: Mirador Therapeutics, Inc.
You may qualify if…
- ✓ Diagnosis of Crohn's Disease (CD), as confirmed by endoscopy and histopathology
- ✓ Moderately to severely active CD as defined by Clinical Disease Activity Index (CDAI) and Simple Endoscopic Score (SES-CD)
- ✓ Meets drug stabilization requirements
- ✓ Diagnosis of Ulcerative Colitis (UC), as confirmed by endoscopy and histopathology
- ✓ Moderately to severely active UC as defined by a 3-component MMCS
- ✓ Meets drug stabilization requirements
You may not qualify if…
- ✕ Diagnosis of indeterminate colitis
- ✕ Suspected or diagnosed intra-abdominal or perianal abscess at Screening
- ✕ Previous small bowel resection with combined resected length of \> 100 cm or previous colonic resection of \> 2 segments
- ✕ CD isolated to the stomach, duodenum, jejunum, or perianal region, without colonic and/or ileal involvement
- ✕ Current evidence or within recent history (within last 6 months) of fulminant colitis, toxic megacolon, or bowel perforation
- ✕ Current stoma or impending need for colostomy or ileostomy
- ✕ Received IV corticosteroids within 14 days prior to Screening or during the Screening Phase
- ✕ Previous total proctocolectomy or subtotal colectomy
Where it's recruiting
Birmingham
Scottsdale · Sun City
Little Rock
Colorado Springs · Littleton
Miami · Orlando · Palmetto Bay · Pensacola
Atlanta · Snellville
Glenview · Gurnee
Lafayette · Marrero · Shreveport
Ypsilanti
Bridgeton · Kansas City · Liberty
Las Vegas
New York · Rochester
Source: ClinicalTrials.gov · NCT07113522 · last updated 2026-03-12